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A B S T R A C T
Leishmaniasis is a Neglected Tropical Disease caused by the insect-vector borne protozoan parasite, Leishmania
species. Infection affects millions of the World's poorest, however vaccines are absent and drug therapy limited.
Recently, public-private partnerships have developed to identify new modes of controlling leishmaniasis. Most of
these collaborative efforts have relied upon the small molecule synthetic compound libraries held by industry,
but the number of New Chemical Entities (NCE) identified and entering development as antileishmanials has
been very low. In light of this, here we describe a public-private effort to identify natural products with activity
against Leishmania mexicana, a causative agent of cutaneous leishmanaisis (CL). Utilising Hypha Discovery's
fungal extract library which is rich in small molecule (< 500 molecular weight) secondary metabolites, we
undertook an iterative phenotypic screening and fractionation approach to identify potent and selective antil-
eishmanial hits. This led to the identification of a novel oxidised bisabolane sesquiterpene which demonstrated
activity in an infected cell model and was shown to disrupt multiple processes using a metabolomic approach. In
addition, and importantly, this study also sets a precedent for new approaches for CL drug discovery.
1. Introduction
The Neglected Tropical Disease (NTD) leishmaniasis is endemic in
over 90 countries worldwide, affecting approximately 12 million people
per year with 350 million people living at risk of disease. The causative
agent, Leishmania species, are sand fly borne kinetoplastid protozoan
parasites (Stuart et al., 2008) and infection leads to a wide spectrum of
clinical manifestations in endemic areas, from self-healing but scarring
cutaneous leishmaniasis (CL) to fatal visceral disease (VL). Amongst
other factors, this diversity of disease is dependent on the parasite
species, host immunity and genetic background (Reithinger et al.,
2007). Largely due to elimination efforts in south Asia, the global
burden of VL has decreased substantially in the past decade. However,
due to forced migration, the cases of CL have substantially increased in
the same period (0.7–1 million per year) (Burza et al., 2018).
A vaccine to prevent leishmaniasis is not available and treatment
relies entirely on a limited arsenal of chemotherapeutics. Recent years
have seen the emergence of public-private partnerships which have
used industrial scale (> 1,000,000) compound libraries to screen for
antileishmanials either phenotypically (Khare et al., 2016; Pena et al.,
2015) or target-based (Norcliffe et al., 2018). However, all the major
initiatives have focused on VL leaving CL, the most common form of
leishmaniasis, as a neglected NTD. Current treatment of CL largely re-
lies on the pentavalent antimonials such as sodium stibogluconate
(Pentostam) and meglumine antimoniate (Glucantime) (Croft and
Coombs, 2003; Kedzierski et al., 2009). Both Pentostam and Glu-
cantime have been in clinical use for over 70 years despite their asso-
ciated problems, which include severe side-effects such as cardiotoxi-
city (Chappuis et al., 2007) and the fact that they require parenteral
administration (Demicheli et al., 2004). In addition, the use of penta-
valent antimonials in the treatment of leishmaniasis is under threat
from the emergence of drug resistance (Croft et al., 2006). Amphoter-
icin B (Fungizone) (Thakur et al., 1999) and diamidine pentamidine
(Bray et al., 2003) are employed as second-line drugs in the treatment
of CL. Like the antimonials, they induce severe side-effects and parasite
resistance, although not yet conclusively confirmed in the field, has
been observed under laboratory conditions (Di Giorgio et al., 1999).
Given the aforementioned issues with both the current first- and
second-line drugs used to treat CL there is clearly a need to develop new
and effective therapies for this disease.
Natural products have long formed the backbone of traditional
therapies, including for leishmaniasis (Charlton et al., 2018; Cockram
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and Smith, 2018). The active compounds of these medicines include
vast numbers of alkaloids (Mishra et al., 2009), flavonoids (da Silva
et al., 2012; Mittra et al., 2000), chalcones (Aponte et al., 2010; Boeck
et al., 2006; Chen et al., 1994; de Mello et al., 2014) and terpenoids
(Arruda et al., 2005; do Socorro et al., 2003). It should also be noted
that the second-line CL drug amphotericin B is itself a natural product,
originally isolated from Streptomyces nodosus as an antifungal in 1955
(Dutcher, 1968).
Given this history, it is logical to consider the natural world as a
potential source of novel antileishmanials. Hypha Discovery's (http://
www.hyphadiscovery.co.uk) large-scale extract (HDLSX) library of
1–5 L volume fermentation extracts is derived from the company's un-
ique collection of higher fungal strains, namely the mushroom-produ-
cing basidiomycetes and ascomycetes, which are underexplored in the
field of antiprotozoal drug discovery. The producing strains included in
the library are regarded as being biosynthetically talented since they
had all demonstrated production of bioactivity in various whole cell-
based assays against microbial pathogens and/or human tumour cell
lines. In this paper we describe a collaborative effort to exploit this
resource for the discovery of novel antileishmanials. Utilising an
iterative process of screening against the CL pathogen Leishmania
mexicana and mammalian cells, followed by fractionation and scale up
of identified parasite selective hits, following dereplication we identi-
fied a known antileishmanial class and, more importantly, a novel
oxidised bisabolane sesquiterpene which demonstrated activity in an
infected cell model. The mode of action of this latter hit was in-
vestigated using a metabolomics approach.
2. Materials and Methods
2.1. HDLSX library generation and format
Scale-up fermentations of fungi selected for inclusion in the HDLSX
library were obtained in multiple shake flasks (each 250 mL Erlenmeyer
flask containing 100 mL Leatham's medium, contents per litre of water:
D-Glucose (25.00 g), L(+)-glutamic acid monosodium salt mono-
hydrate (3.20 g), KH2PO4 (2.00 g), MgSO4.7H2O (2.00 g), mineral so-
lution (10mL), trace element solution (1.0 mL), vitamin solution
(1.0 mL) and 1% aqueous salicylic acid (0.10mL)) to a total volume of
1–5 L. The fermentations were harvested after the same period of time
that yielded the original activity of interest and this could vary from as
little as three to as many as one hundred days. Aqueous broth actives
were harvested by various methods depending on the polarities of the
components of interest including extraction with ethyl acetate or cap-
ture using Diaion HP20 resin and elution with methanol/acetonitrile.
Biomass actives were extracted using methanol-acetone (1:1). The ex-
tracts were concentrated to dryness for storage. The extracts were
weighed and portions stored in 96-well blocks as 10mg/mL solutions in
DMSO. All of the purification and bioactive compound identification
work described within this manuscript was conducted on the initially
available HDLSX library materials without the need for refermentation
of the producing fungal strains, as per the original intention of the li-
brary. For subsequent analyses, further HD871-1 material was obtained
by refermentation.
2.2. Cell culture
Leishmania mexicana (MNYC/BZ/62/M379) were maintained at
26 °C in Schneider's Drosophila media (Sigma Aldrich) supplemented
with heat inactivated foetal bovine sera (HIFBS; 15% for promastigotes,
and 20% for amastigotes; Biosera). Promastigotes were transformed
into axenic amastigotes by a pH and temperature shift as previously
described (Bates, 1994). Ceropithecus aethiops kidney (Vero) cells (ATCC
CCL-81) and Mus musculus leukaemia virus transformed macrophage
(RAW267.4) cells (ATCC TIB-71) were cultured in Dulbecco's Modified
Eagles Medium (DMEM; Fisher Scientific) supplemented with 10%
HIFBS (Biosera). Cells were counted using a Neubauer Improved Hae-
mocytometer.
2.3. Screening against axenic amastigote forms
Cytotoxicity analyses were performed in 96-well plates (Nunc) using
alamarBlue® (Life Technologies) with some modifications to the pub-
lished, optimized protocol (Chadbourne et al., 2011). Briefly, in initial
screens, extracts or isolated compounds were incubated with 100 μL
axenic amastigote L. mexicana at 5× 105 mL−1 for 24 h at 33 °C before
the addition of 10 μL of alamarBlue® and incubation for a further for
24 h at the same temperature, all in Parafilm (Fisher Scientific) sealed
plates. Counter screening was performed against Vero cells, with plates
seeded with 5×103 cells per well. Following overnight incubation at
37 °C, 5% CO2, cells were incubated with extracts or isolated com-
pounds in 100 μL of media for 24 h in the same conditions and then for
a further 4 h following the addition of 10 μL of alamarBlue®. Subse-
quently cell viability was assessed using a fluorescent plate reader
(Biotek; 560EX nm/600 EM nm), with amphotericin B as positive
(10 μM) and DMSO as negative controls.
Initial screening of the HDLSX library (313 extracts) was carried out
using a dose response approach, in duplicate against both axenic
amastigote L. mexicana and mammalian Vero cells. The Selectivity
Index (SI) was calculated from these data (EC50 Vero / EC50 L. mex-
icana). Subsequent fractions were screened at single concentrations in
duplicate against the parasite. Determination of the EC50 of the iden-
tified novel antileishmanial against axenic amastigote L. mexicana was
carried out using the same assay in triplicate on three separate occa-
sions to ensure a robust data set was collected.
2.4. Screening against infected macrophages
Efficacy against L. mexicana infected macrophages was tested as
previously described (Bolt et al., 2016; Eggimann et al., 2015). The
RAW264.7 cells were seeded in 96-well plates at 2.5× 105 mL−1 (200
μL/well) in DMEM (10% HIFBS) and incubated for 24 h at 37 °C, 5%
CO2. Following washing with DMEM (2% HIFBS), L. mexicana axenic
amastigotes (or not for RAW264.7 cytotoxicity) were added at 25× 105
mL−1 (200 μL/well) in DMEM (2% HIFBS) and plate incubated for 24 h
at 37 °C, 5% CO2. Subsequently, the infected RAW264.7 cells were
washed carefully 5× with DMEM (2% HIFBS) before adding 100 μL/
well of fresh DMEM (2% HIFBS) to each well. Isolated compounds and
control (10 μM amphotericin B and DMSO vehicle) were added at the
required concentrations before a further incubation for 24 h at 37 °C,
5% CO2. Finally, the infected macrophages cells were washed 3× with
Schneider's Insect medium (serum-free) and then lysed with 20 μL/well
of SDS (0.05%, v/v in Schneider's) for 30 s before the addition of 180
μL/well of Schneider's Insect medium (pH7, 15% HIFBS). Plates were
Parafilm sealed and incubated for 48 h at 26 °C. Subsequently, 10 μL of
alamarBlue® was added to each well before a 4 h incubation at 26 °C
prior to assessing parasite viability using a fluorescent plate reader
(Biotek; 560EX nm/ 600 EM nm). All of the experiments described
above were carried out on a three separate occasions in triplicate to
ensure a robust data set was collected. The Selectivity Index (SI) was
calculated from these data (EC50 RAW267.4 / EC50 intracellular L.
mexicana).
2.5. Assay-guided purification
Preliminary small-scale activity-guided purification studies on hits
from 12 organisms that showed promising antiparasitic activity profiles
(EC50 < 1mg/mL; therapeutic index> 100) were conducted using
semi-preparative HPLC approaches as follows: extract aliquots (0.9 mL)
were chromatographed by reversed phase HPLC on an Xbridge Prep
Phenyl 5 μm OBD column (19mm×100mm) with a guard column
(19mm×10mm), using gradient elution of 10–100% acetonitrile in
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water in the presence of 0.1% formic acid over 8min, held at 100%
acetonitrile for 3min before returning to starting conditions over
1min at a flow rate of 17mL/min. 24 fractions were collected for each
fractionation and concentrated to dryness in a Genevac HT12 cen-
trifugal evaporator. The resulting dried fractions were re-dissolved in
DMSO-MeOH (3:1, 0.45mL) and aliquots (25 μL) transferred to 96 well
microtiter plates, lyophilised for shipping.
Analysis of active fractions by HPLC-mass spectrometry employing
an orthogonal reversed phase HPLC-MS method was conducted on a
SymmetryShield RP8 column (3.5 μm; 4.6 mm× 75 mm) eluted with a
linear gradient of 10–95% MeCN in water, containing 10 mM ammo-
nium formate + 0.1% formic acid, at a flow rate of 1 mL/min, held at
95% MeCN for 1.0 min before returning to initial conditions over
0.5min; total run time 12 min. UV–visible spectra were acquired using a
Waters 2996 photodiode array detector and positive and negative ion
electrospray mass spectra were acquired using a Waters Acquity SQ
detector. Putative molecular weights, UV–Visible maxima and produ-
cing organism taxonomic data were used to search two natural products
databases to identify known compounds, namely Antibase and the
Chapman and Hall Dictionary of Natural Products.
Specific chromatographic methods were then developed for the
most promising active primary fractions to separate and resolve their
constituent components / HPLC peaks using a reversed phase column
chemistry orthogonal to that used for the primary fractionation step
(usually SymmetryShield RP8). The primary fraction was then fractio-
nated on the semi-preparative scale and individual HPLC peaks col-
lected into secondary fractions that were concentrated to dryness, re-
dissolved and shipped for assay as described above.
2.6. Scale-up purification and structure elucidation
The target extracts were purified by preparative HPLC methods
scaled-up from the purification methods developed from the small-scale
assay guided purification investigations. HD871-1 was purified from
the Diaion HP20 extract of a 5.0 L fermentation of Marasmius sp.
HFN871. The extract was first chromatographed by preparative HPLC
on a Waters Nova-Pak C18 column (40 × 100 mm with a 40 × 10 mm
guard column) eluted with a gradient increasing linearly from 10 to
95% acetonitrile in water containing 0.1% formic acid over a period of
8 min at a flow rate of 50 mL/min. HPLC was used to check for the
presence of the target metabolite with MH + at m/z 263 and this was
present in fractions eluting between 4.5 and 5.5 min. These were
combined and further purified by semi-preparative HPLC on a Waters
Atlantis T3 ODS column (10 × 250 mm) eluted isocratically with 45%
aqueous acetonitrile containing 0.1% formic acid at a flow rate of
4.6 mL/min. HPLC-MS analysis showed that the compound of interest
was present in fractions eluting from 8 to 9 min. A final purification
step was achieved by semi-preparative HPLC on a Waters X-Select C18
column (19 × 100 mm with a 19 × 10 mm guard column) eluted with
a linear gradient increasing from 25 to 30% aqueous acetonitrile con-
taining 0.1% formic acid over a period of 14 min at a flow rate of
20 mL/min. The peak eluting at 10 min was collected and concentrated
to dryness to yield pure HD871-1 (6.9 mg) as a colourless residue. 1H
and 13C NMR spectra were acquired at 500MHz and 125MHz, re-
spectively, at 298K in DMSO-d6, on a Bruker AVANCE III 500MHz
NMR spectrometer at the University of Surrey, Guildford, UK. Datasets
for structure elucidation included COSY, HSQC, HMBC and NOESY
spectra, which were interpreted at Hypha Discovery using Mestrenova
software. High resolution mass spectrometry was conducted on a
Bruker micrOTOF-Q instrument.
2.7. Metabolite extraction
The optimal concentration of HD871-1 for this experiment was es-
tablished by estimation of the half time of L. mexicana axenic amasti-
gotes to death at 4 concentrations (1.25, 2.5, 5 and 10 μM) by
microscopic observation at 12, 24, 36 and 48 h. Subsequently the
amastigotes, seeded at 1×107 parasites/mL, were exposed to 10 μM
HD871-1, or a vehicle (DMSO) control, for 36 h at 32 °C. Metabolites
were then extracted and analysed as follows:
For LC-MS metabolomic analyses, sample extraction was performed
as described (Creek et al., 2011; Kovářová et al., 2018). In summary,
108 cells were rapidly cooled in a dry ice/ethanol bath to 4 °C, cen-
trifuged, washed with 1 × PBS, and resuspended in 200 μL extraction
solvent (chloroform:methanol:water, 1:3:1 vol ratio). Samples were
centrifuged at 16,000 g (4 °C for 10min) after shaking for 1 h at 4 °C.
The supernatant was stored under argon at −80 °C until running on the
mass spectrometer. Samples were first separated using HPLC with a
150× 4.6mm ZIC-pHILIC (Merck) column on UltiMate 3000 RSLC
(Thermo Scientific). Mass detection used an Orbitrap Q-Exactive mass
spectrometer (Thermo Fisher) at Glasgow Polyomics, using positive and
negative polarity switching mode, with a 10 μL injection volume and
flow rate of 300 μL/min 249 authentic standards were included to assist
compound identification. Data were processed and analysed using
mzMatch (Scheltema et al., 2011) and IDEOM software (Creek et al.,
2012). All the MS analyses were performed in at least triplicate. The
Comparison page of the IDEOM file is included as supplementary ma-
terial (Supplementary Table 1). This contains information on those
masses detected as likely metabolites through the software processing.
Exact mass is measured and this is converted, where possible to a for-
mula corresponding to that mass. Screening of a database of metabo-
lites with that formula then yields a putative identity. Where an au-
thentic standard has a matching mass and retention time this is taken as
a likely hit. Other annotations are tentative (metabolomics standards
initiative level 2, Sumner et al., 2007) with this data.
3. Results
3.1. Primary screening
Utilising a 96-well protocol previously developed to identify antil-
eishmanial compounds (Chadbourne et al., 2011) the HDLSX library
(313 fungal extracts) was screened against mammalian stage L. mex-
icana axenic amastigotes in a dose response experiment. Extracts in-
hibiting with an EC50 < 0.025mg/mL (Effective Concentration eli-
citing 50% inhibition of proliferation) against the parasites were
selected, and these 38 hits counter screened in the same manner against
mammalian Vero cells. These hits represent complex mixtures with
non-cytotoxic extracts possibly containing minor cytotoxic components,
and conversely, non-active extracts may harbour minor antiparasitic
components. However, to narrow down the extracts for further ana-
lyses, based on the screening data, potent hits with a selectivity index
(SI)> 48 were initially selected. After subtracting those with known
cytotoxicity and intellectual property issues we were left with 17 hits.
Based on Hypha data, replicated extracts were removed leaving 12 hits
(HDLSX-9, 14, 18, 21, 22, 33, 35, 67, 79, 127, 159, 171; Table 1), a hit
rate of 3.8%.
3.2. Primary fractionation and secondary screening
As described in Materials and Methods primary fractionation was
undertaken of the 12 hits, yielding 24 fractions per sample. 10 of the
initial 12 hits had components demonstrating complete cytotoxic ac-
tivity against axenic amastigotes at 1mg/mL (fractions from HDLSX-9,
18, 21, 22, 35, 67, 79, 159, 171, 127; Fig. 1). Initial analyses by mass
spectrometry indicated the complexity and, in some cases, content of
the active fractions. For example, striatals (including striatal B) were
present in HDLSX-21 (from HFN65 Cyathus cf. crassimurus). This was
confirmed by chromatographic comparison with a pure sample of
striatal B previously isolated from a Cyathus sp. fermentation at Hypha.
The 1H NMR spectrum of this material is shown in Supplementary
Figure 1 and the signals observed are consistent with those previously
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reported for striatal B (Anke et al., 2002). Notably the striatals have
previously demonstrated to be antileishmanial (Inchausti et al., 1997)
(Fig. 2). A pure sample of the related compound striatal C was tested
and found to have an ED50 of< 0.8 μM, but considerable toxicity to
mammalian cells. Other compounds identified at this stage and de-
prioritised were a glycolipid from HDLSX-18 (HFN67, Dacryopinax sp.),
which had low potency with an ED50 > 100 μM, and the known me-
tabolite nitidon from HDLSX-67 (HFN528 Junghuhnia nitida), which is
cytotoxic against other cell lines (Gehrt et al., 1998). The active HDLSX-
79 fractions were also dereplicated due to chemical overlap with the
HDLSX-22 fractions. This dereplication process left 8 active primary
extract fractions to take forward to secondary fractionation and ana-
lyses - two from HDLSX-9, and one each from HDLSX-21, 22, 35, 127,
159, 171.
3.3. Secondary fractionation and tertiary screening
Secondary fractions were undertaken of the 8 remaining active
primary fractions demonstrating chemical novelty (two from HDLSX-9,
and one each from HDLSX-21, 22, 35, 127, 159, 171). These isolated
factions were screened against axenic amastigotes at 1mg/mL. HDLSX-
9, 22, and 127 derived secondary fractions had components demon-
strating complete cytotoxic activity against axenic amastigotes, further
fractionation of the 5 other primary fractions (including from HDLSX-
21 not containing striatal B) did not yield samples with high level ac-
tivity (Fig. 3). Given that the fractions were screened at equivalent
concentrations (1 mg/mL) it is likely that the apparent loss of activity
on further fractionation of these 5 samples was due to a loss of the
additive antileishmanial efficacy observed in the initial mixture of
compounds. Initial analyses by mass spectrometry indicated the com-
plexity and, in some cases, content of the active fractions. Informed by
these analyses, secondary fractions were screened against axenic
amastigotes if pure (HDLSX9Fr9+10F7 and HDLSX127Fr11Fr9; Fig. 3A
and G) or further fractionated (from HDLSX-22; Fig. 3D) before
screening. The pure HDLSX-9 (HDLSX9Fr9+10F7) secondary fraction
had minimal activity against the L. mexicana amastigotes
(EC50 > 100 μM; data not shown). Furthermore, none of the HDLSX-22
tertiary fractions demonstrated complete cytotoxicity against axenic
amastigotes at 1mg/mL (data not shown). In contrast, the pure HDLSX-
127 secondary fraction (HD871-1; HDLSX-127Fr11Fr9 in Fig. 3G)
showed good activity (EC50= 4.73 μM) against the parasite. Further-
more, utilising a previous established assay (Bolt et al., 2016; Eggimann
et al., 2015), this compound was tested against infected macrophages
and for macrophage cytotoxicity, demonstrating a promising profile
with respect to efficacy (EC50= 4.32 μM) and selectivity (5.51) (Fig. 4).
3.4. Structure elucidation of HD871-1
The ESI-MS spectrum of HD871-1 showed a molecular ion [MH]+ at
m/z 263, indicating a molecular weight of 262. High resolution mass
measurement of the sodiated molecular ion yielded an m/z value of
285.1095 Da, consistent with a molecular formula of C15H18O4 (the
calculated value for C15H18NaO4 is 285.1097 Da). The UV spectrum of
HD871-1 showed a maximum absorbance at 226 nm, suggesting the
Table 1
The 38 potent hits (EC50 < 0.025mg/ml against axenic amastigote L. mexicana) were counter screened against mammalian Vero cells. Those with a selectivity index
(SI)> 48 were initially selected. Final selection (12 hits, Y in bold) was made after subtracting those with known cytotoxicity and intellectual property issues, and de-
replication.
Compound number Amastigote EC50 mg/ml Vero EC50 mg/ml Selectivity index (SI) SI > 48 Selection
HDLSX-171 3.37E-16 > 1.33E+00 >3.95E+15 Y Y
HDLSX-106 2.45E-02 1.07E-02 4.38E-01 N N
HDLSX-67 1.31E-04 6.35E-03 4.84E+01 Y Y
HDLSX-33 5.22E-04 >1.33E+00 >2.55E+03 Y Y
HDLSX-134 6.66E-04 3.28E-04 4.92E-01 N N
HDLSX-14 6.84E-04 >1.33E+00 >1.94E+03 Y Y
HDLSX-159 7.94E-04 3.96E-01 4.99E+02 Y Y
HDLSX-127 9.26E-04 >1.33E+00 >1.44E+03 Y Y
HDLSX-21 2.72E-03 1.34E-01 4.92E+01 Y Y
HDLSX-208 2.77E-03 > 1.33E+00 >4.80E+02 Y N
HDLSX-79 3.26E-03 1.83E+00 5.61E+02 Y Y
HDLSX-27 3.36E-03 9.97E-03 2.97E+00 N N
HDLSX-177 3.56E-03 > 1.33E+00 >3.73E+02 Y N
HDLSX-84 4.84E-03 1.07E-01 2.21E+01 N N
HDLSX-23 5.09E-03 2.29E-01 4.50E+01 N N
HDLSX-179 5.94E-03 1.37E-01 2.31E+01 N N
HDLSX-130 6.75E-03 > 1.33E+00 >1.97E+02 Y N
HDLSX-209 6.86E-03 4.40E-02 6.41E+00 N N
HDLSX-18 7.15E-03 >1.33E+00 >1.86E+02 Y Y
HDLSX-22 7.42E-03 >1.33E+00 >1.79E+02 Y Y
HDLSX-39 7.55E-03 6.92E-02 9.17E+00 N N
HDLSX-213 9.05E-03 > 1.33E+00 >1.47E+02 Y N
HDLSX-13 9.24E-03 > 1.33E+00 >1.44E+02 Y N
HDLSX-72 9.53E-03 1.69E-01 1.77E+01 N N
HDLSX-126 1.02E-02 > 1.33E+00 >1.30E+02 Y N
HDLSX-114 1.03E-02 5.92E-03 5.73E-01 N N
HDLSX-37 1.18E-02 9.93E-02 8.42E+00 N N
HDLSX-35 1.37E-02 >1.33E+00 >9.71E+01 Y Y
HDLSX-163 1.44E-02 7.71E-01 5.34E+01 Y N
HDLSX-180 1.47E-02 > 1.33E+00 >9.06E+01 Y N
HDLSX-9 1.47E-02 >1.33E+00 >9.03E+01 Y Y
HDLSX-8 1.48E-02 7.26E-02 4.92E+00 N N
HDLSX-40 1.61E-02 9.71E-02 6.05E+00 N N
HDLSX-44 1.74E-02 > 1.33E+00 >7.63E+01 Y N
HDLSX-28 1.78E-02 1.32E-01 7.45E+00 N N
HDLSX-85 1.89E-02 > 1.33E+00 >7.04E+01 Y N
HDLSX-211 1.90E-02 > 1.33E+00 >7.00E+01 Y N
HDLSX-145 2.06E-02 7.91E-01 3.85E+01 N N
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presence of an α,β-unsaturated carbonyl moiety. The 1H and 13C NMR
data for HD871-1 are summarised in Table 2 and the 1H, COSY, HSQC,
HMBC and NOESY NMR spectra are presented in Supplementary
Figures 2-6 respectively. The 13C signals were detected indirectly
through the heteronuclear shift correlation HSQC and HMBC spectra
and were found to comprise two methyl carbons, four methylene car-
bons including an olefinic methylene group, four methine carbons in-
cluding an olefinic methine and five quaternary carbons. Inspection of
the 1H–1H COSY spectrum indicated the presence of two fragments
comprising C6–C1–C2–C3 and C9–C10–C11–C13 as shown in Fig. 5.
HMBC correlations from the methyl proton signal at 1.80 ppm (15-CH3)
with carbon signals at 143.3, 135.9 and 198.4 ppm (corresponding to
positions 2, 3 and 4, respectively) and from the methylene proton sig-
nals at 2.55 and 2.44 ppm (5-CH2) with the carbon signals at 198.4,
36.1 and 31.5 ppm (positions 4, 6 and 1) established the presence of a
cyclohexenone ring. HMBC correlations from the olefinic methylene
protons at 6.23 and 6.00 ppm to carbons at 36.1, 148.0 and 194.5 ppm
(positions 6, 7 and 8) established the connectivity of these with the
cyclohexenone moiety. HMBC correlations the methyl proton signal at
1.31 ppm with carbon signals at 33.1, 34.7 and 178.2 ppm were con-
sistent with the presence of a butanolide ring. Although there were no
HMBC correlations to connect this with the rest of the molecule, its
Figure 1. Screening of primary fractions of the 12 hits against against axenic amastigote L. mexicana at 1mg/ml y-axis shows proliferation (%) relative to vehicle
(DMSO) treated control. Each selected extract (HDLSX-9, 14, 18, 21, 22, 33, 35, 67, 79, 127, 159, 171) was fractionated into 24 fractions, e.g. HDSLX9.1, 9.3 etc. For
clarity, only odd number fractions are labelled on the x-axis.
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linkage as shown in Fig. 5 was supported by NOE correlations in the
NOESY spectrum between the olefinic methylene protons at 6.23 and
6.00 ppm (14-CH2) and the 9-oxymethine proton at 5.31 ppm. HD871-1
is therefore proposed to be a novel bisabolane sesquiterpene with a high
degree of oxygenation and unsaturation.
3.5. Untargeted metabolomics assessment of metabolic perturbation induced
by HD871-1
Metabolomics can enable identification of drug targets where these
targets represent metabolic enzymes (Vincent and Barrett, 2015). For
example, treatment of African trypanosomes with the drug eflornithine
(difluoromethylornithine; DFMO) lead to profound increases in or-
nithine and loss of putrescine and spermidine, which relates to the drug
being an inhibitor of the enzyme ornithine decarboxylase (Vincent
et al., 2012). The untargeted metabolomics approach we took does not
identify all metabolites within the metabolome, but it does probe many
pathways and is able to indicate key areas of perturbed metabolism.
The data is reported in Supplementary Table 1. Although multiple
peptides and also lipids were noted to change profoundly, we discarded
these from further consideration. Peptides often reveal profound
changes in kinetoplastids exposed to different drugs as protein turnover
is influenced in unpredictable ways. Lipids are not resolved using the
hydrophilic chromatography platform used here, hence they tend to
Figure 2. A peak (6.5min) in fraction 14 of HDLSX-21 had a product MH+ m/z 489.6 and MNH4+ m/z 506.6 in the positive ion spectrum (starred in A); and [M-H]-
m/z 487.6 in the negative ion spectrum (starred in B). This corresponded to known antimicrobial striatal B (C).
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elute at the solvent front during chromatography and suffer poor peak
shapes and multitudinous ion suppression effects. Substantial changes
did, however, occur to metabolism across many pathways under the
conditions used (Fig. 6). However, a clear, individual target could not
be identified. Of note was an increase in deoxynucleotide monopho-
sphates and a decrease in deoxynucleotide diphosphates (Fig. 7). These
changes point to alterations in nucleotide homeostasis and metabolism,
but the impact on cell viability is not certain. Profound decreases in
orotate and dihydroorotate also point to an impact on pyrimidine bio-
synthesis, but pyrimidines themselves are not diminished, presumably
due to the parasite's ability to transport and interconvert pyrimidines
(Alzahrani et al., 2017). In the absence of the ability to synthesize the
purine ring, salvage is essential for Leishmania viability (Boitz et al.,
2012; Martin et al., 2016). The increase in dAMP and dGMP (Fig. 7)
indicated this process was unaffected by HD871-1 treatment. However,
dADP was substantially decreased suggesting that further
phosphorylation maybe inhibited (Fig. 7). It was also noteworthy that a
mass consistent with trypanothione, the bis(glutathionyl) spermidine
adduct that performs key redox roles in Leishmania spp and other try-
panosomatids, was greatly diminished in treated cells. The peak of this
compound (m/z= 361.6527 corresponding to the doubly positively
charged trypanothione) was poorly resolved by chromatography, hence
quantitative comparison is not possible, but treated cells contained
profoundly less signal for this mass than untreated cells. In addition to
reduced trypanothione, its oxidised disulphide derivative, (m/
z=361.6441), was also 3–4 fold less abundant in treated cells, and its
thiol precursor glutathione (mz=307.0837) also diminished in abun-
dance by>60% in the treated cells. Another poorly resolved peak
consistent with the oxidised cysteine derivative, cystine
(mz= 240.0238) was identified in treated, but not untreated cells. This
accumulated data points to the cells having been exposed to oxidative
stresses over the treatment regime.
Figure 3. Screening of secondary fractions of the 8 active primary fractions (two from HDLSX-9, and one each from HDLSX-21, 22, 35, 127, 159, 171) against axenic
amastigote L. mexicana at 1 mg/ml x-axis shows the secondary fractions from the following primary extract fractions: A HDLSX9 fractions 9 and 10
(HDLSX9Fr9+10); B HDLSX9 fraction 13 (HDLSX9Fr13); C HDLSX21 fraction 1 (HDLSX21Fr1); D HDLSX22 fractions 13 and 14 (HDLSX22Fr13 + 14); E HDLSX35
fraction 17 (HDLSX35Fr17); F HDLSX159 fractions 12 and 13 (HDLSX159Fr12 + 13); G HDLSX127 fraction 11 (HDLSX127Fr11); H HDLSX171 fraction 7
(HDLSX171Fr7). y-axis shows proliferation (%) relative to vehicle (DMSO) treated control.
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4. Discussion
Given the paucity of safe and effective therapies for CL, and a rising
number of cases in an increasing geographic area, the search for novel
antileishmanials is as urgent as ever and natural product discovery
forms part of this global effort (Charlton et al., 2018; Cockram and
Smith, 2018). In this study, using an iterative screening and
fractionation approach, we ‘mined’ the HDLSX library (313 fungal ex-
tracts, enriched in small molecule secondary metabolites) for com-
pounds showing activity against Leishmania mexicana. A pure secondary
fractionation component, HD871-1 (molecular weight of 262), was
identified as a potent antileishmanial which demonstrated activity in an
infected cell model (Fig. 4). This compound was characterised as a
novel bisabolane sesquiterpene with a high degree of oxygenation and
Figure 3. (continued)
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unsaturation (Fig. 5, Table 2). HD871-1 has structural similarities to
cheimonophyllons A-E, bisabolane sesquiterpenes isolated from fer-
mentations of the basidiomycete Cheimonophyllum candidissimum,
which have been shown to demonstrate nematicidal properties (Stadler
and Anke, 1994). Taken together, these studies indicate that this class
of compounds could represent a new class of broad-spectrum of anti-
parasitics.
However, to best take forward and develop any antileishmanial/
antiparasitic the identification of the mode of action is key. To begin
deconvolution of the target of HD871-1, in this study metabolomics was
used to identify changes to the metabolic network of L. mexicana
amastigotes exposed to HD871-1. Using a 36 h timepoint and com-
pound dose 2-fold higher than the EC50, a number of clear changes to
metabolism occurred (Supplementary Table 1), although a single clear
hit pointing to a specific enzyme targeted by the drug was not apparent
(as had been found, for example, using eflornithine against T. brucei,
Vincent et al., 2012). Changes in the deoxynucleotide pool indicated
possible changes in nucleotide homeostasis and metabolism, although
whether this is a cause of cell death, or a secondary effect due to other
changes is not clear. Loss of the chief redox reactive thiol trypanothione
and accumulation of cystine pointed to oxidative stress being induced
by HD871-1. The presence of two α,β-unsaturated ketone moieties in
the structure of HD871-1 with the potential to act as Michael acceptors
suggests a likely reactive nature towards appropriate nucleophiles such
as trypanothione and glutathione. Since both reduced and oxidised
trypanothione were diminished, as was glutathione, a possible role in
drug binding prior to efflux from the cell, as occurs in the parasite re-
sponse to antimony (Wyllie et al., 2004), would be worthy of future
investigation.
Figure 4. HD871-1 activity against L. mexicana axenic amastigotes (red plot
line: EC50 = 4.73 μM; 95% Confidence Interval [CI] 3.65–6.12 μM); in-
tramacrophage amastigotes with RAW264.7 cells (black plot line: EC50 =
4.32 μM; 95% CI 3.03–6.15 μM); uninfected RAW264.7 macrophages (blue plot
line: EC50 = 23.8 μM; 95% CI 20.9–27.1 μM). From these data the compound
was calculated to have a selectivity index of 5.51.
Table 2
1H and 13C NMR assignments for HD871-1 in CDCl3, referenced to internal TMS
at 0.00 ppm
Position HD871-1
δH/ppm, m (J/Hz) δC/ppm
1 2.51, m; 2.27, ddt (18.0, 10.5, 2.5) 31.5
2 6.73, m 143.3
3 135.9
4 198.4
5 2.55, ddd (16.0, 3.9, 1.4); 2.44, dd (16.0, 12.8) 42.8
6 3.35, m 36.1
7 148.0
8 194.5
9 5.31, dd (9.2, 7.1) 77.0
10 2.62, m; 2.02, m 33.1
11 2.75, m 34.7
12 178.2
13 1.31, d (7.1) 15.5
14 6.23, s; 6.00, s 127.0
15 1.80, s 16.1
Figure 5. Structure of HD871-1 (A); key COSY, HMBC and NOE correlations
(B).
Figure 6. Principle Component Analysis (PCA) plot showing the global differ-
ences between treated and untreated cells. Five replicates of the measured
metabolites from untreated (blue dots) and treated with HD871 (red dots). The
green dots show pooled samples from both types and indicate good reprodu-
cibility across the machine run. PC1 and 2=Principle Components.
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5. Conclusions
Using an iterative process of screening and fractionation a novel
bisabolane sesquiterpene antileishmanial was identified from a fungal
extract library. Metabolomic analyses indicated that the compound
induced oxidative stress in the parasite. Further analyses are required to
fully define the mode of action, however the process described sets a
precedent for the discovery of much needed novel antileishmanials.
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